Skip to Main Content

Paper Details

Corrigendum to "A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival" [Leukemia Res. 104 March (2021)].
Leuk Res
0
2021
Author NameAffiliation
Ronan SwordsAbbVie Inc.
Guillermo Garcia-ManeroUniversity of Texas, M.D. Anderson Cancer Center
David P SteensmaDana-Farber Cancer Institute
  • 1 - 3

Datasets

Release 1.2